As gene therapy trials for Retinitis Punctata Albescens (RPA) advance, determining which patients are most likely to benefit is a critical challenge. A recent study reviewed the clinical and genetic data of 21 patients from 15 families carrying biallelic pathogenic variants in the RLBP1 gene to establish clear genotype-phenotype correlations and define eligibility criteria for treatment.
The research analyzed various clinical parameters, including age at onset, visual acuity, visual field, and structural changes measured by spectral-domain optical coherence tomography (SD-OCT). The study identified that the preservation of specific retinal structures, such as the ellipsoid zone (EZ) and interdigitation zone (IZ), are crucial indicators of viable photoreceptors that could respond to gene therapy.
The findings suggest that eligibility for RLBP1 gene therapy should first be determined by the specific biallelic variant combination, as different mutations can lead to varying disease severities, such as the more severe Bothnia dystrophy or Newfoundland rod-cone dystrophy. Furthermore, the study proposed lower limiting values for macular thickness and ellipsoid line width as prerequisite imaging indicators for trial inclusion.
By establishing these detailed clinical and genetic criteria, researchers can better select candidates for gene therapy, maximizing the chances of successful outcomes and ensuring that the therapy is administered to those with sufficient remaining retinal structure to benefit from the restoration of the visual cycle.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.